nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RALBP1—coronary artery disease	0.156	0.487	CbGaD
Sorafenib—KDR—coronary artery disease	0.0695	0.218	CbGaD
Sorafenib—KIT—coronary artery disease	0.0656	0.205	CbGaD
Sorafenib—CYP2C19—coronary artery disease	0.0286	0.0894	CbGaD
Sorafenib—ABCC2—Olmesartan—coronary artery disease	0.0101	0.0259	CbGbCtD
Sorafenib—ABCC4—Rosuvastatin—coronary artery disease	0.01	0.0257	CbGbCtD
Sorafenib—UGT1A1—Ezetimibe—coronary artery disease	0.00977	0.0251	CbGbCtD
Sorafenib—UGT1A1—Simvastatin—coronary artery disease	0.00909	0.0233	CbGbCtD
Sorafenib—UGT1A1—Lovastatin—coronary artery disease	0.00889	0.0228	CbGbCtD
Sorafenib—ABCC4—Atorvastatin—coronary artery disease	0.00828	0.0213	CbGbCtD
Sorafenib—UGT1A1—Atorvastatin—coronary artery disease	0.0081	0.0208	CbGbCtD
Sorafenib—ABCC2—Pitavastatin—coronary artery disease	0.00807	0.0207	CbGbCtD
Sorafenib—ABCC2—Telmisartan—coronary artery disease	0.00807	0.0207	CbGbCtD
Sorafenib—UGT1A1—Losartan—coronary artery disease	0.00741	0.019	CbGbCtD
Sorafenib—ABCG2—Pitavastatin—coronary artery disease	0.00729	0.0187	CbGbCtD
Sorafenib—ABCG2—Telmisartan—coronary artery disease	0.00729	0.0187	CbGbCtD
Sorafenib—CYP2C8—Fenofibrate—coronary artery disease	0.00641	0.0165	CbGbCtD
Sorafenib—ABCC2—Ezetimibe—coronary artery disease	0.00595	0.0153	CbGbCtD
Sorafenib—CYP2B6—Clopidogrel—coronary artery disease	0.00587	0.0151	CbGbCtD
Sorafenib—CYP3A7—Eplerenone—coronary artery disease	0.00573	0.0147	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Eplerenone—coronary artery disease	0.00573	0.0147	CbGbCtD
Sorafenib—ABCC2—Simvastatin—coronary artery disease	0.00553	0.0142	CbGbCtD
Sorafenib—ABCC2—Lovastatin—coronary artery disease	0.00541	0.0139	CbGbCtD
Sorafenib—ABCC2—Pravastatin—coronary artery disease	0.00541	0.0139	CbGbCtD
Sorafenib—ABCG2—Ezetimibe—coronary artery disease	0.00538	0.0138	CbGbCtD
Sorafenib—ABCG2—Rosuvastatin—coronary artery disease	0.00538	0.0138	CbGbCtD
Sorafenib—CYP2C8—Gemfibrozil—coronary artery disease	0.00513	0.0132	CbGbCtD
Sorafenib—ABCC2—Atorvastatin—coronary artery disease	0.00493	0.0126	CbGbCtD
Sorafenib—ABCG2—Pravastatin—coronary artery disease	0.00489	0.0126	CbGbCtD
Sorafenib—ABCB1—Ticagrelor—coronary artery disease	0.00487	0.0125	CbGbCtD
Sorafenib—CYP3A5—Clopidogrel—coronary artery disease	0.00462	0.0119	CbGbCtD
Sorafenib—ABCC2—Furosemide—coronary artery disease	0.0046	0.0118	CbGbCtD
Sorafenib—CYP2C9—Fenofibrate—coronary artery disease	0.00447	0.0115	CbGbCtD
Sorafenib—CYP2C8—Clopidogrel—coronary artery disease	0.00444	0.0114	CbGbCtD
Sorafenib—CYP2C19—Gemfibrozil—coronary artery disease	0.0043	0.011	CbGbCtD
Sorafenib—CYP3A5—Eplerenone—coronary artery disease	0.0043	0.011	CbGbCtD
Sorafenib—CYP1A2—Gemfibrozil—coronary artery disease	0.00397	0.0102	CbGbCtD
Sorafenib—CYP2C8—Pitavastatin—coronary artery disease	0.00388	0.00997	CbGbCtD
Sorafenib—CYP2C19—Clopidogrel—coronary artery disease	0.00373	0.00957	CbGbCtD
Sorafenib—CYP3A7—Simvastatin—coronary artery disease	0.00369	0.00947	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Simvastatin—coronary artery disease	0.00369	0.00947	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Lovastatin—coronary artery disease	0.00361	0.00927	CbGbCtD
Sorafenib—CYP3A7—Lovastatin—coronary artery disease	0.00361	0.00927	CbGbCtD
Sorafenib—CYP2C9—Gemfibrozil—coronary artery disease	0.00357	0.00918	CbGbCtD
Sorafenib—CYP2B6—Simvastatin—coronary artery disease	0.00351	0.00902	CbGbCtD
Sorafenib—CYP1A2—Clopidogrel—coronary artery disease	0.00344	0.00883	CbGbCtD
Sorafenib—CYP3A7—Atorvastatin—coronary artery disease	0.00329	0.00844	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Atorvastatin—coronary artery disease	0.00329	0.00844	CbGbCtD
Sorafenib—CYP2C19—Telmisartan—coronary artery disease	0.00326	0.00836	CbGbCtD
Sorafenib—CYP2B6—Atorvastatin—coronary artery disease	0.00313	0.00804	CbGbCtD
Sorafenib—CYP2C9—Clopidogrel—coronary artery disease	0.0031	0.00796	CbGbCtD
Sorafenib—ABCB1—Clopidogrel—coronary artery disease	0.00301	0.00772	CbGbCtD
Sorafenib—ABCB1—Perindopril—coronary artery disease	0.00301	0.00772	CbGbCtD
Sorafenib—CYP3A5—Rosuvastatin—coronary artery disease	0.00298	0.00764	CbGbCtD
Sorafenib—CYP3A4—Ticagrelor—coronary artery disease	0.00292	0.00749	CbGbCtD
Sorafenib—HTR2B—cardial valve—coronary artery disease	0.00284	0.0595	CbGeAlD
Sorafenib—CYP2C8—Acetylsalicylic acid—coronary artery disease	0.00279	0.00716	CbGbCtD
Sorafenib—CYP3A5—Simvastatin—coronary artery disease	0.00277	0.00711	CbGbCtD
Sorafenib—CYP3A5—Pravastatin—coronary artery disease	0.00271	0.00695	CbGbCtD
Sorafenib—CYP3A5—Lovastatin—coronary artery disease	0.00271	0.00695	CbGbCtD
Sorafenib—CYP2C9—Pitavastatin—coronary artery disease	0.00271	0.00695	CbGbCtD
Sorafenib—CYP2C8—Simvastatin—coronary artery disease	0.00266	0.00683	CbGbCtD
Sorafenib—CYP2C9—Valsartan—coronary artery disease	0.00264	0.00676	CbGbCtD
Sorafenib—ABCB1—Telmisartan—coronary artery disease	0.00263	0.00675	CbGbCtD
Sorafenib—ABCB1—Pitavastatin—coronary artery disease	0.00263	0.00675	CbGbCtD
Sorafenib—CYP2C19—Timolol—coronary artery disease	0.00263	0.00674	CbGbCtD
Sorafenib—CYP2C8—Pravastatin—coronary artery disease	0.00261	0.00669	CbGbCtD
Sorafenib—CYP2C8—Lovastatin—coronary artery disease	0.00261	0.00669	CbGbCtD
Sorafenib—CYP3A4—Fenofibrate—coronary artery disease	0.0026	0.00667	CbGbCtD
Sorafenib—ABCB1—Enalapril—coronary artery disease	0.00249	0.0064	CbGbCtD
Sorafenib—ABCB1—Lisinopril—coronary artery disease	0.00249	0.0064	CbGbCtD
Sorafenib—CYP3A5—Atorvastatin—coronary artery disease	0.00247	0.00633	CbGbCtD
Sorafenib—CYP2C19—Rosuvastatin—coronary artery disease	0.0024	0.00617	CbGbCtD
Sorafenib—CYP2C8—Atorvastatin—coronary artery disease	0.00237	0.00609	CbGbCtD
Sorafenib—CYP2C19—Acetylsalicylic acid—coronary artery disease	0.00234	0.00601	CbGbCtD
Sorafenib—CYP3A5—Losartan—coronary artery disease	0.00226	0.00579	CbGbCtD
Sorafenib—CYP2C19—Simvastatin—coronary artery disease	0.00223	0.00573	CbGbCtD
Sorafenib—CYP2C19—Lovastatin—coronary artery disease	0.00219	0.00561	CbGbCtD
Sorafenib—CYP2C8—Losartan—coronary artery disease	0.00217	0.00557	CbGbCtD
Sorafenib—CYP2D6—Niacin—coronary artery disease	0.00215	0.00551	CbGbCtD
Sorafenib—ABCB1—Timolol—coronary artery disease	0.00212	0.00544	CbGbCtD
Sorafenib—CYP3A4—Gemfibrozil—coronary artery disease	0.00208	0.00534	CbGbCtD
Sorafenib—CYP2C9—Rosuvastatin—coronary artery disease	0.002	0.00513	CbGbCtD
Sorafenib—CYP2D6—Timolol—coronary artery disease	0.002	0.00513	CbGbCtD
Sorafenib—CYP2C19—Atorvastatin—coronary artery disease	0.00199	0.00511	CbGbCtD
Sorafenib—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.00195	0.005	CbGbCtD
Sorafenib—ABCB1—Ezetimibe—coronary artery disease	0.00194	0.00498	CbGbCtD
Sorafenib—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00189	0.00485	CbGbCtD
Sorafenib—ABCB1—Captopril—coronary artery disease	0.00187	0.00479	CbGbCtD
Sorafenib—CYP2C9—Simvastatin—coronary artery disease	0.00186	0.00477	CbGbCtD
Sorafenib—CYP2C9—cardial valve—coronary artery disease	0.00184	0.0386	CbGeAlD
Sorafenib—CYP2C19—Losartan—coronary artery disease	0.00182	0.00467	CbGbCtD
Sorafenib—CYP2C9—Pravastatin—coronary artery disease	0.00182	0.00466	CbGbCtD
Sorafenib—CYP2C9—Lovastatin—coronary artery disease	0.00182	0.00466	CbGbCtD
Sorafenib—CYP3A4—Clopidogrel—coronary artery disease	0.0018	0.00463	CbGbCtD
Sorafenib—ABCB1—Simvastatin—coronary artery disease	0.0018	0.00463	CbGbCtD
Sorafenib—ABCB1—Lovastatin—coronary artery disease	0.00176	0.00453	CbGbCtD
Sorafenib—ABCB1—Pravastatin—coronary artery disease	0.00176	0.00453	CbGbCtD
Sorafenib—CYP2D6—Captopril—coronary artery disease	0.00176	0.00451	CbGbCtD
Sorafenib—CYP2D6—Simvastatin—coronary artery disease	0.0017	0.00436	CbGbCtD
Sorafenib—CYP1A2—Losartan—coronary artery disease	0.00168	0.00431	CbGbCtD
Sorafenib—CYP3A4—Eplerenone—coronary artery disease	0.00168	0.0043	CbGbCtD
Sorafenib—CYP2D6—Pravastatin—coronary artery disease	0.00166	0.00426	CbGbCtD
Sorafenib—CYP2D6—Lovastatin—coronary artery disease	0.00166	0.00426	CbGbCtD
Sorafenib—CYP2C9—Atorvastatin—coronary artery disease	0.00165	0.00425	CbGbCtD
Sorafenib—ABCB1—Atorvastatin—coronary artery disease	0.00161	0.00412	CbGbCtD
Sorafenib—CYP2C9—Losartan—coronary artery disease	0.00151	0.00389	CbGbCtD
Sorafenib—CYP2D6—Atorvastatin—coronary artery disease	0.00151	0.00388	CbGbCtD
Sorafenib—CYP3A4—Enalapril—coronary artery disease	0.00149	0.00383	CbGbCtD
Sorafenib—RET—autonomic nervous system—coronary artery disease	0.00147	0.0309	CbGeAlD
Sorafenib—ABCB1—Losartan—coronary artery disease	0.00147	0.00377	CbGbCtD
Sorafenib—Regorafenib—TEK—coronary artery disease	0.00123	0.417	CrCbGaD
Sorafenib—CYP3A4—Ezetimibe—coronary artery disease	0.00116	0.00298	CbGbCtD
Sorafenib—CYP3A4—Rosuvastatin—coronary artery disease	0.00116	0.00298	CbGbCtD
Sorafenib—CDKL3—heart—coronary artery disease	0.00111	0.0233	CbGeAlD
Sorafenib—CYP3A4—Simvastatin—coronary artery disease	0.00108	0.00277	CbGbCtD
Sorafenib—CYP3A4—Pravastatin—coronary artery disease	0.00106	0.00271	CbGbCtD
Sorafenib—CYP3A4—Lovastatin—coronary artery disease	0.00106	0.00271	CbGbCtD
Sorafenib—CDKL3—cardiovascular system—coronary artery disease	0.00105	0.0219	CbGeAlD
Sorafenib—TIE1—endothelium—coronary artery disease	0.000966	0.0203	CbGeAlD
Sorafenib—CYP3A4—Atorvastatin—coronary artery disease	0.000962	0.00247	CbGbCtD
Sorafenib—CYP3A4—Losartan—coronary artery disease	0.00088	0.00226	CbGbCtD
Sorafenib—FLT4—endothelium—coronary artery disease	0.000798	0.0167	CbGeAlD
Sorafenib—FLT1—artery—coronary artery disease	0.000734	0.0154	CbGeAlD
Sorafenib—HIPK3—cardiac ventricle—coronary artery disease	0.000686	0.0144	CbGeAlD
Sorafenib—HIPK3—myocardium—coronary artery disease	0.000645	0.0135	CbGeAlD
Sorafenib—KDR—artery—coronary artery disease	0.000621	0.013	CbGeAlD
Sorafenib—FLT1—endothelium—coronary artery disease	0.00062	0.013	CbGeAlD
Sorafenib—TIE1—myocardium—coronary artery disease	0.000603	0.0127	CbGeAlD
Sorafenib—Regorafenib—KDR—coronary artery disease	0.000599	0.204	CrCbGaD
Sorafenib—Regorafenib—KIT—coronary artery disease	0.000565	0.192	CrCbGaD
Sorafenib—MAPK11—heart—coronary artery disease	0.000541	0.0114	CbGeAlD
Sorafenib—CDK7—heart—coronary artery disease	0.000533	0.0112	CbGeAlD
Sorafenib—TAOK2—heart—coronary artery disease	0.000528	0.0111	CbGeAlD
Sorafenib—KDR—endothelium—coronary artery disease	0.000524	0.011	CbGeAlD
Sorafenib—AURKC—heart—coronary artery disease	0.000524	0.011	CbGeAlD
Sorafenib—MAP3K7—cardiac ventricle—coronary artery disease	0.000495	0.0104	CbGeAlD
Sorafenib—FGFR1—myocardium—coronary artery disease	0.000492	0.0103	CbGeAlD
Sorafenib—MKNK2—cardiac ventricle—coronary artery disease	0.00048	0.0101	CbGeAlD
Sorafenib—MKNK1—cardiac ventricle—coronary artery disease	0.000474	0.00993	CbGeAlD
Sorafenib—MAP3K7—myocardium—coronary artery disease	0.000466	0.00976	CbGeAlD
Sorafenib—KIT—endothelium—coronary artery disease	0.000465	0.00975	CbGeAlD
Sorafenib—ZAK—heart—coronary artery disease	0.00046	0.00966	CbGeAlD
Sorafenib—MKNK2—myocardium—coronary artery disease	0.000451	0.00946	CbGeAlD
Sorafenib—HIPK3—heart—coronary artery disease	0.00045	0.00945	CbGeAlD
Sorafenib—MKNK1—myocardium—coronary artery disease	0.000445	0.00934	CbGeAlD
Sorafenib—ZAK—cardiovascular system—coronary artery disease	0.000434	0.00911	CbGeAlD
Sorafenib—RALBP1—cardiac ventricle—coronary artery disease	0.000433	0.00909	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—coronary artery disease	0.000425	0.00892	CbGeAlD
Sorafenib—TIE1—heart—coronary artery disease	0.000421	0.00883	CbGeAlD
Sorafenib—FLT1—cardiac ventricle—coronary artery disease	0.000412	0.00864	CbGeAlD
Sorafenib—RAF1—cardiac ventricle—coronary artery disease	0.00041	0.00859	CbGeAlD
Sorafenib—RALBP1—myocardium—coronary artery disease	0.000407	0.00855	CbGeAlD
Sorafenib—BRAF—heart—coronary artery disease	0.000404	0.00847	CbGeAlD
Sorafenib—TIE1—cardiovascular system—coronary artery disease	0.000397	0.00833	CbGeAlD
Sorafenib—TAOK2—blood—coronary artery disease	0.000394	0.00827	CbGeAlD
Sorafenib—FLT1—myocardium—coronary artery disease	0.000388	0.00813	CbGeAlD
Sorafenib—EPHX2—heart—coronary artery disease	0.000386	0.00809	CbGeAlD
Sorafenib—RAF1—myocardium—coronary artery disease	0.000385	0.00808	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—coronary artery disease	0.000385	0.00808	CbGeAlD
Sorafenib—FLT3—heart—coronary artery disease	0.000383	0.00803	CbGeAlD
Sorafenib—FLT3—cardiovascular system—coronary artery disease	0.000361	0.00758	CbGeAlD
Sorafenib—TIE1—cardiac atrium—coronary artery disease	0.00036	0.00755	CbGeAlD
Sorafenib—KDR—cardiac ventricle—coronary artery disease	0.000348	0.00731	CbGeAlD
Sorafenib—FLT4—heart—coronary artery disease	0.000348	0.0073	CbGeAlD
Sorafenib—ZAK—blood—coronary artery disease	0.000344	0.00721	CbGeAlD
Sorafenib—FGFR1—heart—coronary artery disease	0.000343	0.0072	CbGeAlD
Sorafenib—HIPK3—blood—coronary artery disease	0.000336	0.00705	CbGeAlD
Sorafenib—FLT4—cardiovascular system—coronary artery disease	0.000328	0.00689	CbGeAlD
Sorafenib—MAP2K5—myocardium—coronary artery disease	0.000328	0.00687	CbGeAlD
Sorafenib—KDR—myocardium—coronary artery disease	0.000328	0.00687	CbGeAlD
Sorafenib—MAP3K7—heart—coronary artery disease	0.000325	0.00682	CbGeAlD
Sorafenib—MKNK2—heart—coronary artery disease	0.000315	0.00661	CbGeAlD
Sorafenib—MKNK1—heart—coronary artery disease	0.000311	0.00652	CbGeAlD
Sorafenib—RET—heart—coronary artery disease	0.000307	0.00644	CbGeAlD
Sorafenib—PDGFRB—cardiac ventricle—coronary artery disease	0.000301	0.00632	CbGeAlD
Sorafenib—BRAF—blood—coronary artery disease	0.000301	0.00632	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—coronary artery disease	0.000297	0.00623	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—coronary artery disease	0.000294	0.00616	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—coronary artery disease	0.000293	0.00615	CbGeAlD
Sorafenib—KIT—myocardium—coronary artery disease	0.00029	0.00609	CbGeAlD
Sorafenib—EPHX2—blood—coronary artery disease	0.000288	0.00604	CbGeAlD
Sorafenib—FLT3—blood—coronary artery disease	0.000286	0.006	CbGeAlD
Sorafenib—RALBP1—heart—coronary artery disease	0.000284	0.00597	CbGeAlD
Sorafenib—PDGFRB—myocardium—coronary artery disease	0.000284	0.00595	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—coronary artery disease	0.000278	0.00583	CbGeAlD
Sorafenib—FLT1—heart—coronary artery disease	0.000271	0.00567	CbGeAlD
Sorafenib—MKNK2—cardiac atrium—coronary artery disease	0.000269	0.00565	CbGeAlD
Sorafenib—RAF1—heart—coronary artery disease	0.000269	0.00564	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—coronary artery disease	0.000268	0.00563	CbGeAlD
Sorafenib—EPHB6—heart—coronary artery disease	0.000267	0.00561	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—coronary artery disease	0.000266	0.00558	CbGeAlD
Sorafenib—FLT4—blood—coronary artery disease	0.00026	0.00545	CbGeAlD
Sorafenib—STK10—heart—coronary artery disease	0.000256	0.00537	CbGeAlD
Sorafenib—FLT1—cardiovascular system—coronary artery disease	0.000255	0.00535	CbGeAlD
Sorafenib—RAF1—cardiovascular system—coronary artery disease	0.000254	0.00532	CbGeAlD
Sorafenib—PDGFRA—heart—coronary artery disease	0.000253	0.00532	CbGeAlD
Sorafenib—Regorafenib—CYP2C19—coronary artery disease	0.000246	0.0837	CrCbGaD
Sorafenib—RALBP1—cardiac atrium—coronary artery disease	0.000243	0.0051	CbGeAlD
Sorafenib—MAP3K7—blood—coronary artery disease	0.000242	0.00509	CbGeAlD
Sorafenib—STK10—cardiovascular system—coronary artery disease	0.000242	0.00507	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—coronary artery disease	0.000239	0.00502	CbGeAlD
Sorafenib—MKNK2—blood—coronary artery disease	0.000235	0.00493	CbGeAlD
Sorafenib—MKNK1—blood—coronary artery disease	0.000232	0.00487	CbGeAlD
Sorafenib—FLT1—cardiac atrium—coronary artery disease	0.000231	0.00485	CbGeAlD
Sorafenib—RAF1—cardiac atrium—coronary artery disease	0.00023	0.00482	CbGeAlD
Sorafenib—RET—blood—coronary artery disease	0.000229	0.00481	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—coronary artery disease	0.000229	0.0048	CbGeAlD
Sorafenib—KDR—heart—coronary artery disease	0.000229	0.0048	CbGeAlD
Sorafenib—MAP2K5—heart—coronary artery disease	0.000229	0.0048	CbGeAlD
Sorafenib—CSF1R—heart—coronary artery disease	0.000223	0.00468	CbGeAlD
Sorafenib—KDR—cardiovascular system—coronary artery disease	0.000216	0.00453	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—coronary artery disease	0.000216	0.00453	CbGeAlD
Sorafenib—RALBP1—blood—coronary artery disease	0.000212	0.00445	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—coronary artery disease	0.000211	0.00442	CbGeAlD
Sorafenib—KIT—heart—coronary artery disease	0.000203	0.00425	CbGeAlD
Sorafenib—FLT1—blood—coronary artery disease	0.000202	0.00423	CbGeAlD
Sorafenib—RAF1—blood—coronary artery disease	0.000201	0.00421	CbGeAlD
Sorafenib—EPHB6—blood—coronary artery disease	0.0002	0.00419	CbGeAlD
Sorafenib—PDGFRB—heart—coronary artery disease	0.000198	0.00415	CbGeAlD
Sorafenib—KDR—cardiac atrium—coronary artery disease	0.000196	0.0041	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—coronary artery disease	0.000196	0.0041	CbGeAlD
Sorafenib—Vismodegib—CYP2C19—coronary artery disease	0.000195	0.0664	CrCbGaD
Sorafenib—KIT—cardiovascular system—coronary artery disease	0.000191	0.00401	CbGeAlD
Sorafenib—STK10—blood—coronary artery disease	0.000191	0.00401	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—coronary artery disease	0.000191	0.004	CbGeAlD
Sorafenib—PDGFRA—blood—coronary artery disease	0.000189	0.00397	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—coronary artery disease	0.000187	0.00392	CbGeAlD
Sorafenib—UGT1A1—blood—coronary artery disease	0.00018	0.00379	CbGeAlD
Sorafenib—KDR—blood—coronary artery disease	0.000171	0.00358	CbGeAlD
Sorafenib—MAP2K5—blood—coronary artery disease	0.000171	0.00358	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—coronary artery disease	0.000169	0.00355	CbGeAlD
Sorafenib—CSF1R—blood—coronary artery disease	0.000167	0.00349	CbGeAlD
Sorafenib—ABCC4—heart—coronary artery disease	0.000158	0.00331	CbGeAlD
Sorafenib—HTR2B—heart—coronary artery disease	0.000157	0.00329	CbGeAlD
Sorafenib—KIT—blood—coronary artery disease	0.000151	0.00317	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—coronary artery disease	0.000148	0.0031	CbGeAlD
Sorafenib—PDGFRB—blood—coronary artery disease	0.000148	0.0031	CbGeAlD
Sorafenib—ABCC4—blood—coronary artery disease	0.000118	0.00247	CbGeAlD
Sorafenib—HTR2B—blood—coronary artery disease	0.000117	0.00245	CbGeAlD
Sorafenib—ABCC2—blood—coronary artery disease	0.000114	0.00239	CbGeAlD
Sorafenib—ABCG2—heart—coronary artery disease	0.000111	0.00233	CbGeAlD
Sorafenib—Vismodegib—ALB—coronary artery disease	0.000108	0.0368	CrCbGaD
Sorafenib—CYP2B6—heart—coronary artery disease	0.000103	0.00215	CbGeAlD
Sorafenib—CYP2C9—heart—coronary artery disease	0.000102	0.00213	CbGeAlD
Sorafenib—CYP2C19—blood—coronary artery disease	9.78e-05	0.00205	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—coronary artery disease	9.68e-05	0.00203	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—coronary artery disease	9.59e-05	0.00201	CbGeAlD
Sorafenib—CYP2C8—blood—coronary artery disease	8.54e-05	0.00179	CbGeAlD
Sorafenib—ABCG2—blood—coronary artery disease	8.3e-05	0.00174	CbGeAlD
Sorafenib—CYP1A2—blood—coronary artery disease	7.99e-05	0.00168	CbGeAlD
Sorafenib—CYP3A5—blood—coronary artery disease	7.71e-05	0.00162	CbGeAlD
Sorafenib—CYP2B6—blood—coronary artery disease	7.66e-05	0.00161	CbGeAlD
Sorafenib—CYP2C9—blood—coronary artery disease	7.58e-05	0.00159	CbGeAlD
Sorafenib—CYP3A4—blood—coronary artery disease	5.78e-05	0.00121	CbGeAlD
Sorafenib—CYP2D6—blood—coronary artery disease	5.69e-05	0.00119	CbGeAlD
Sorafenib—ABCB1—heart—coronary artery disease	5.49e-05	0.00115	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—coronary artery disease	5.18e-05	0.00109	CbGeAlD
Sorafenib—ABCB1—blood—coronary artery disease	4.09e-05	0.000859	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	3.54e-05	0.000292	CcSEcCtD
Sorafenib—Dermatitis—Clopidogrel—coronary artery disease	3.54e-05	0.000292	CcSEcCtD
Sorafenib—Asthenia—Valsartan—coronary artery disease	3.54e-05	0.000292	CcSEcCtD
Sorafenib—Hypertension—Timolol—coronary artery disease	3.53e-05	0.000292	CcSEcCtD
Sorafenib—Constipation—Furosemide—coronary artery disease	3.53e-05	0.000292	CcSEcCtD
Sorafenib—Pain—Furosemide—coronary artery disease	3.53e-05	0.000292	CcSEcCtD
Sorafenib—Hypersensitivity—Niacin—coronary artery disease	3.53e-05	0.000291	CcSEcCtD
Sorafenib—Asthenia—Olmesartan—coronary artery disease	3.52e-05	0.000291	CcSEcCtD
Sorafenib—Headache—Clopidogrel—coronary artery disease	3.52e-05	0.00029	CcSEcCtD
Sorafenib—Rash—Lovastatin—coronary artery disease	3.52e-05	0.00029	CcSEcCtD
Sorafenib—Dermatitis—Lovastatin—coronary artery disease	3.51e-05	0.00029	CcSEcCtD
Sorafenib—Anaemia—Lisinopril—coronary artery disease	3.51e-05	0.00029	CcSEcCtD
Sorafenib—Dyspepsia—Losartan—coronary artery disease	3.51e-05	0.00029	CcSEcCtD
Sorafenib—Headache—Lovastatin—coronary artery disease	3.49e-05	0.000289	CcSEcCtD
Sorafenib—Pruritus—Valsartan—coronary artery disease	3.49e-05	0.000288	CcSEcCtD
Sorafenib—Dry mouth—Ramipril—coronary artery disease	3.49e-05	0.000288	CcSEcCtD
Sorafenib—Arthralgia—Timolol—coronary artery disease	3.48e-05	0.000288	CcSEcCtD
Sorafenib—Myalgia—Timolol—coronary artery disease	3.48e-05	0.000288	CcSEcCtD
Sorafenib—Vomiting—Ezetimibe—coronary artery disease	3.48e-05	0.000287	CcSEcCtD
Sorafenib—Hypersensitivity—Pravastatin—coronary artery disease	3.48e-05	0.000287	CcSEcCtD
Sorafenib—Gastrointestinal pain—Perindopril—coronary artery disease	3.47e-05	0.000287	CcSEcCtD
Sorafenib—Angioedema—Lisinopril—coronary artery disease	3.47e-05	0.000286	CcSEcCtD
Sorafenib—Pruritus—Olmesartan—coronary artery disease	3.47e-05	0.000286	CcSEcCtD
Sorafenib—Decreased appetite—Losartan—coronary artery disease	3.46e-05	0.000286	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	3.46e-05	0.000286	CcSEcCtD
Sorafenib—Abdominal pain—Captopril—coronary artery disease	3.46e-05	0.000286	CcSEcCtD
Sorafenib—Body temperature increased—Captopril—coronary artery disease	3.46e-05	0.000286	CcSEcCtD
Sorafenib—Dizziness—Simvastatin—coronary artery disease	3.45e-05	0.000285	CcSEcCtD
Sorafenib—Rash—Ezetimibe—coronary artery disease	3.45e-05	0.000285	CcSEcCtD
Sorafenib—Dermatitis—Ezetimibe—coronary artery disease	3.45e-05	0.000285	CcSEcCtD
Sorafenib—Asthenia—Niacin—coronary artery disease	3.44e-05	0.000284	CcSEcCtD
Sorafenib—Fatigue—Losartan—coronary artery disease	3.44e-05	0.000284	CcSEcCtD
Sorafenib—Headache—Ezetimibe—coronary artery disease	3.43e-05	0.000283	CcSEcCtD
Sorafenib—Anaphylactic shock—Ramipril—coronary artery disease	3.42e-05	0.000282	CcSEcCtD
Sorafenib—Dry mouth—Timolol—coronary artery disease	3.41e-05	0.000281	CcSEcCtD
Sorafenib—Constipation—Losartan—coronary artery disease	3.41e-05	0.000281	CcSEcCtD
Sorafenib—Pain—Losartan—coronary artery disease	3.41e-05	0.000281	CcSEcCtD
Sorafenib—Syncope—Lisinopril—coronary artery disease	3.4e-05	0.000281	CcSEcCtD
Sorafenib—Vomiting—Eplerenone—coronary artery disease	3.4e-05	0.000281	CcSEcCtD
Sorafenib—Leukopenia—Lisinopril—coronary artery disease	3.4e-05	0.000281	CcSEcCtD
Sorafenib—Nausea—Fenofibrate—coronary artery disease	3.39e-05	0.00028	CcSEcCtD
Sorafenib—Pruritus—Niacin—coronary artery disease	3.39e-05	0.00028	CcSEcCtD
Sorafenib—Asthenia—Pravastatin—coronary artery disease	3.38e-05	0.000279	CcSEcCtD
Sorafenib—Gastrointestinal pain—Furosemide—coronary artery disease	3.38e-05	0.000279	CcSEcCtD
Sorafenib—Rash—Eplerenone—coronary artery disease	3.38e-05	0.000279	CcSEcCtD
Sorafenib—Urticaria—Perindopril—coronary artery disease	3.38e-05	0.000279	CcSEcCtD
Sorafenib—Hypersensitivity—Trandolapril—coronary artery disease	3.37e-05	0.000279	CcSEcCtD
Sorafenib—Dermatitis—Eplerenone—coronary artery disease	3.37e-05	0.000279	CcSEcCtD
Sorafenib—Diarrhoea—Valsartan—coronary artery disease	3.37e-05	0.000278	CcSEcCtD
Sorafenib—Shock—Ramipril—coronary artery disease	3.36e-05	0.000278	CcSEcCtD
Sorafenib—Hypersensitivity—Enalapril—coronary artery disease	3.36e-05	0.000278	CcSEcCtD
Sorafenib—Body temperature increased—Perindopril—coronary artery disease	3.36e-05	0.000277	CcSEcCtD
Sorafenib—Abdominal pain—Perindopril—coronary artery disease	3.36e-05	0.000277	CcSEcCtD
Sorafenib—Diarrhoea—Olmesartan—coronary artery disease	3.35e-05	0.000277	CcSEcCtD
Sorafenib—Headache—Eplerenone—coronary artery disease	3.35e-05	0.000277	CcSEcCtD
Sorafenib—Nervous system disorder—Ramipril—coronary artery disease	3.35e-05	0.000277	CcSEcCtD
Sorafenib—Thrombocytopenia—Ramipril—coronary artery disease	3.35e-05	0.000276	CcSEcCtD
Sorafenib—Anaphylactic shock—Timolol—coronary artery disease	3.34e-05	0.000276	CcSEcCtD
Sorafenib—Pruritus—Pravastatin—coronary artery disease	3.34e-05	0.000276	CcSEcCtD
Sorafenib—Loss of consciousness—Lisinopril—coronary artery disease	3.34e-05	0.000276	CcSEcCtD
Sorafenib—Nausea—Clopidogrel—coronary artery disease	3.34e-05	0.000275	CcSEcCtD
Sorafenib—Skin disorder—Ramipril—coronary artery disease	3.32e-05	0.000274	CcSEcCtD
Sorafenib—Infection—Timolol—coronary artery disease	3.32e-05	0.000274	CcSEcCtD
Sorafenib—Vomiting—Simvastatin—coronary artery disease	3.32e-05	0.000274	CcSEcCtD
Sorafenib—Hypersensitivity—Telmisartan—coronary artery disease	3.32e-05	0.000274	CcSEcCtD
Sorafenib—Cough—Lisinopril—coronary artery disease	3.31e-05	0.000274	CcSEcCtD
Sorafenib—Nausea—Lovastatin—coronary artery disease	3.31e-05	0.000274	CcSEcCtD
Sorafenib—Rash—Simvastatin—coronary artery disease	3.29e-05	0.000272	CcSEcCtD
Sorafenib—Dermatitis—Simvastatin—coronary artery disease	3.29e-05	0.000271	CcSEcCtD
Sorafenib—Asthenia—Trandolapril—coronary artery disease	3.29e-05	0.000271	CcSEcCtD
Sorafenib—Shock—Timolol—coronary artery disease	3.29e-05	0.000271	CcSEcCtD
Sorafenib—Urticaria—Furosemide—coronary artery disease	3.28e-05	0.000271	CcSEcCtD
Sorafenib—Diarrhoea—Niacin—coronary artery disease	3.28e-05	0.000271	CcSEcCtD
Sorafenib—Nervous system disorder—Timolol—coronary artery disease	3.28e-05	0.00027	CcSEcCtD
Sorafenib—Asthenia—Enalapril—coronary artery disease	3.27e-05	0.00027	CcSEcCtD
Sorafenib—Headache—Simvastatin—coronary artery disease	3.27e-05	0.00027	CcSEcCtD
Sorafenib—Abdominal pain—Furosemide—coronary artery disease	3.26e-05	0.00027	CcSEcCtD
Sorafenib—Body temperature increased—Furosemide—coronary artery disease	3.26e-05	0.00027	CcSEcCtD
Sorafenib—Gastrointestinal pain—Losartan—coronary artery disease	3.26e-05	0.000269	CcSEcCtD
Sorafenib—Dizziness—Valsartan—coronary artery disease	3.26e-05	0.000269	CcSEcCtD
Sorafenib—Anorexia—Ramipril—coronary artery disease	3.26e-05	0.000269	CcSEcCtD
Sorafenib—Nausea—Ezetimibe—coronary artery disease	3.25e-05	0.000268	CcSEcCtD
Sorafenib—Skin disorder—Timolol—coronary artery disease	3.24e-05	0.000268	CcSEcCtD
Sorafenib—Dizziness—Olmesartan—coronary artery disease	3.24e-05	0.000268	CcSEcCtD
Sorafenib—Pruritus—Trandolapril—coronary artery disease	3.24e-05	0.000268	CcSEcCtD
Sorafenib—Arthralgia—Lisinopril—coronary artery disease	3.23e-05	0.000267	CcSEcCtD
Sorafenib—Myalgia—Lisinopril—coronary artery disease	3.23e-05	0.000267	CcSEcCtD
Sorafenib—Asthenia—Telmisartan—coronary artery disease	3.23e-05	0.000267	CcSEcCtD
Sorafenib—Pruritus—Enalapril—coronary artery disease	3.23e-05	0.000267	CcSEcCtD
Sorafenib—Diarrhoea—Pravastatin—coronary artery disease	3.23e-05	0.000266	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	3.21e-05	0.000265	CcSEcCtD
Sorafenib—Anorexia—Timolol—coronary artery disease	3.18e-05	0.000263	CcSEcCtD
Sorafenib—Pruritus—Telmisartan—coronary artery disease	3.18e-05	0.000263	CcSEcCtD
Sorafenib—Nausea—Eplerenone—coronary artery disease	3.18e-05	0.000263	CcSEcCtD
Sorafenib—Dizziness—Niacin—coronary artery disease	3.17e-05	0.000262	CcSEcCtD
Sorafenib—Urticaria—Losartan—coronary artery disease	3.17e-05	0.000261	CcSEcCtD
Sorafenib—Dry mouth—Lisinopril—coronary artery disease	3.16e-05	0.000261	CcSEcCtD
Sorafenib—Abdominal pain—Losartan—coronary artery disease	3.15e-05	0.00026	CcSEcCtD
Sorafenib—Body temperature increased—Losartan—coronary artery disease	3.15e-05	0.00026	CcSEcCtD
Sorafenib—Asthenia—Captopril—coronary artery disease	3.14e-05	0.000259	CcSEcCtD
Sorafenib—Diarrhoea—Trandolapril—coronary artery disease	3.13e-05	0.000259	CcSEcCtD
Sorafenib—Vomiting—Valsartan—coronary artery disease	3.13e-05	0.000259	CcSEcCtD
Sorafenib—Diarrhoea—Enalapril—coronary artery disease	3.12e-05	0.000258	CcSEcCtD
Sorafenib—Dizziness—Pravastatin—coronary artery disease	3.12e-05	0.000258	CcSEcCtD
Sorafenib—Vomiting—Olmesartan—coronary artery disease	3.12e-05	0.000257	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ramipril—coronary artery disease	3.11e-05	0.000257	CcSEcCtD
Sorafenib—Rash—Valsartan—coronary artery disease	3.11e-05	0.000257	CcSEcCtD
Sorafenib—Dermatitis—Valsartan—coronary artery disease	3.1e-05	0.000256	CcSEcCtD
Sorafenib—Nausea—Simvastatin—coronary artery disease	3.1e-05	0.000256	CcSEcCtD
Sorafenib—Anaphylactic shock—Lisinopril—coronary artery disease	3.1e-05	0.000256	CcSEcCtD
Sorafenib—Pruritus—Captopril—coronary artery disease	3.1e-05	0.000256	CcSEcCtD
Sorafenib—Rash—Olmesartan—coronary artery disease	3.09e-05	0.000255	CcSEcCtD
Sorafenib—Dermatitis—Olmesartan—coronary artery disease	3.09e-05	0.000255	CcSEcCtD
Sorafenib—Headache—Valsartan—coronary artery disease	3.09e-05	0.000255	CcSEcCtD
Sorafenib—Diarrhoea—Telmisartan—coronary artery disease	3.08e-05	0.000254	CcSEcCtD
Sorafenib—Infection—Lisinopril—coronary artery disease	3.08e-05	0.000254	CcSEcCtD
Sorafenib—Headache—Olmesartan—coronary artery disease	3.07e-05	0.000254	CcSEcCtD
Sorafenib—Shock—Lisinopril—coronary artery disease	3.05e-05	0.000252	CcSEcCtD
Sorafenib—Asthenia—Perindopril—coronary artery disease	3.05e-05	0.000252	CcSEcCtD
Sorafenib—Dyspnoea—Ramipril—coronary artery disease	3.05e-05	0.000252	CcSEcCtD
Sorafenib—Vomiting—Niacin—coronary artery disease	3.05e-05	0.000252	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Timolol—coronary artery disease	3.04e-05	0.000251	CcSEcCtD
Sorafenib—Hypersensitivity—Furosemide—coronary artery disease	3.04e-05	0.000251	CcSEcCtD
Sorafenib—Thrombocytopenia—Lisinopril—coronary artery disease	3.03e-05	0.000251	CcSEcCtD
Sorafenib—Dizziness—Trandolapril—coronary artery disease	3.03e-05	0.00025	CcSEcCtD
Sorafenib—Rash—Niacin—coronary artery disease	3.02e-05	0.000249	CcSEcCtD
Sorafenib—Dermatitis—Niacin—coronary artery disease	3.02e-05	0.000249	CcSEcCtD
Sorafenib—Dizziness—Enalapril—coronary artery disease	3.02e-05	0.000249	CcSEcCtD
Sorafenib—Skin disorder—Lisinopril—coronary artery disease	3.01e-05	0.000249	CcSEcCtD
Sorafenib—Dyspepsia—Ramipril—coronary artery disease	3.01e-05	0.000248	CcSEcCtD
Sorafenib—Pruritus—Perindopril—coronary artery disease	3.01e-05	0.000248	CcSEcCtD
Sorafenib—Headache—Niacin—coronary artery disease	3e-05	0.000248	CcSEcCtD
Sorafenib—Vomiting—Pravastatin—coronary artery disease	3e-05	0.000248	CcSEcCtD
Sorafenib—Diarrhoea—Captopril—coronary artery disease	2.99e-05	0.000247	CcSEcCtD
Sorafenib—Dyspnoea—Timolol—coronary artery disease	2.98e-05	0.000246	CcSEcCtD
Sorafenib—Dizziness—Telmisartan—coronary artery disease	2.98e-05	0.000246	CcSEcCtD
Sorafenib—Rash—Pravastatin—coronary artery disease	2.97e-05	0.000246	CcSEcCtD
Sorafenib—Dermatitis—Pravastatin—coronary artery disease	2.97e-05	0.000245	CcSEcCtD
Sorafenib—Decreased appetite—Ramipril—coronary artery disease	2.97e-05	0.000245	CcSEcCtD
Sorafenib—Asthenia—Furosemide—coronary artery disease	2.96e-05	0.000245	CcSEcCtD
Sorafenib—Headache—Pravastatin—coronary artery disease	2.95e-05	0.000244	CcSEcCtD
Sorafenib—Anorexia—Lisinopril—coronary artery disease	2.95e-05	0.000244	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ramipril—coronary artery disease	2.95e-05	0.000244	CcSEcCtD
Sorafenib—Fatigue—Ramipril—coronary artery disease	2.95e-05	0.000243	CcSEcCtD
Sorafenib—Dyspepsia—Timolol—coronary artery disease	2.94e-05	0.000243	CcSEcCtD
Sorafenib—Hypersensitivity—Losartan—coronary artery disease	2.94e-05	0.000242	CcSEcCtD
Sorafenib—Nausea—Valsartan—coronary artery disease	2.93e-05	0.000242	CcSEcCtD
Sorafenib—Pruritus—Furosemide—coronary artery disease	2.92e-05	0.000241	CcSEcCtD
Sorafenib—Constipation—Ramipril—coronary artery disease	2.92e-05	0.000241	CcSEcCtD
Sorafenib—Nausea—Olmesartan—coronary artery disease	2.91e-05	0.000241	CcSEcCtD
Sorafenib—Vomiting—Trandolapril—coronary artery disease	2.91e-05	0.00024	CcSEcCtD
Sorafenib—Diarrhoea—Perindopril—coronary artery disease	2.91e-05	0.00024	CcSEcCtD
Sorafenib—Decreased appetite—Timolol—coronary artery disease	2.9e-05	0.00024	CcSEcCtD
Sorafenib—Vomiting—Enalapril—coronary artery disease	2.9e-05	0.00024	CcSEcCtD
Sorafenib—Dizziness—Captopril—coronary artery disease	2.89e-05	0.000239	CcSEcCtD
Sorafenib—Rash—Trandolapril—coronary artery disease	2.89e-05	0.000238	CcSEcCtD
Sorafenib—Dermatitis—Trandolapril—coronary artery disease	2.89e-05	0.000238	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Timolol—coronary artery disease	2.88e-05	0.000238	CcSEcCtD
Sorafenib—Fatigue—Timolol—coronary artery disease	2.88e-05	0.000238	CcSEcCtD
Sorafenib—Rash—Enalapril—coronary artery disease	2.88e-05	0.000238	CcSEcCtD
Sorafenib—Dermatitis—Enalapril—coronary artery disease	2.87e-05	0.000237	CcSEcCtD
Sorafenib—Headache—Trandolapril—coronary artery disease	2.87e-05	0.000237	CcSEcCtD
Sorafenib—Vomiting—Telmisartan—coronary artery disease	2.86e-05	0.000236	CcSEcCtD
Sorafenib—Asthenia—Losartan—coronary artery disease	2.86e-05	0.000236	CcSEcCtD
Sorafenib—Headache—Enalapril—coronary artery disease	2.86e-05	0.000236	CcSEcCtD
Sorafenib—Pain—Timolol—coronary artery disease	2.86e-05	0.000236	CcSEcCtD
Sorafenib—Nausea—Niacin—coronary artery disease	2.85e-05	0.000235	CcSEcCtD
Sorafenib—Rash—Telmisartan—coronary artery disease	2.84e-05	0.000234	CcSEcCtD
Sorafenib—Dermatitis—Telmisartan—coronary artery disease	2.83e-05	0.000234	CcSEcCtD
Sorafenib—Diarrhoea—Furosemide—coronary artery disease	2.83e-05	0.000233	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Lisinopril—coronary artery disease	2.82e-05	0.000233	CcSEcCtD
Sorafenib—Pruritus—Losartan—coronary artery disease	2.82e-05	0.000233	CcSEcCtD
Sorafenib—Headache—Telmisartan—coronary artery disease	2.82e-05	0.000233	CcSEcCtD
Sorafenib—Dizziness—Perindopril—coronary artery disease	2.81e-05	0.000232	CcSEcCtD
Sorafenib—Nausea—Pravastatin—coronary artery disease	2.8e-05	0.000231	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ramipril—coronary artery disease	2.79e-05	0.000231	CcSEcCtD
Sorafenib—Vomiting—Captopril—coronary artery disease	2.78e-05	0.00023	CcSEcCtD
Sorafenib—Dyspnoea—Lisinopril—coronary artery disease	2.76e-05	0.000228	CcSEcCtD
Sorafenib—Rash—Captopril—coronary artery disease	2.76e-05	0.000228	CcSEcCtD
Sorafenib—Dermatitis—Captopril—coronary artery disease	2.76e-05	0.000228	CcSEcCtD
Sorafenib—Headache—Captopril—coronary artery disease	2.74e-05	0.000226	CcSEcCtD
Sorafenib—Gastrointestinal pain—Timolol—coronary artery disease	2.73e-05	0.000226	CcSEcCtD
Sorafenib—Dizziness—Furosemide—coronary artery disease	2.73e-05	0.000226	CcSEcCtD
Sorafenib—Dyspepsia—Lisinopril—coronary artery disease	2.73e-05	0.000225	CcSEcCtD
Sorafenib—Diarrhoea—Losartan—coronary artery disease	2.73e-05	0.000225	CcSEcCtD
Sorafenib—Nausea—Trandolapril—coronary artery disease	2.72e-05	0.000225	CcSEcCtD
Sorafenib—Urticaria—Ramipril—coronary artery disease	2.71e-05	0.000224	CcSEcCtD
Sorafenib—Nausea—Enalapril—coronary artery disease	2.71e-05	0.000224	CcSEcCtD
Sorafenib—Vomiting—Perindopril—coronary artery disease	2.7e-05	0.000223	CcSEcCtD
Sorafenib—Abdominal pain—Ramipril—coronary artery disease	2.7e-05	0.000223	CcSEcCtD
Sorafenib—Body temperature increased—Ramipril—coronary artery disease	2.7e-05	0.000223	CcSEcCtD
Sorafenib—Decreased appetite—Lisinopril—coronary artery disease	2.69e-05	0.000222	CcSEcCtD
Sorafenib—Rash—Perindopril—coronary artery disease	2.68e-05	0.000221	CcSEcCtD
Sorafenib—Dermatitis—Perindopril—coronary artery disease	2.68e-05	0.000221	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Lisinopril—coronary artery disease	2.68e-05	0.000221	CcSEcCtD
Sorafenib—Nausea—Telmisartan—coronary artery disease	2.67e-05	0.000221	CcSEcCtD
Sorafenib—Fatigue—Lisinopril—coronary artery disease	2.67e-05	0.000221	CcSEcCtD
Sorafenib—Headache—Perindopril—coronary artery disease	2.66e-05	0.00022	CcSEcCtD
Sorafenib—Urticaria—Timolol—coronary artery disease	2.65e-05	0.000219	CcSEcCtD
Sorafenib—Pain—Lisinopril—coronary artery disease	2.65e-05	0.000219	CcSEcCtD
Sorafenib—Constipation—Lisinopril—coronary artery disease	2.65e-05	0.000219	CcSEcCtD
Sorafenib—Body temperature increased—Timolol—coronary artery disease	2.64e-05	0.000218	CcSEcCtD
Sorafenib—Abdominal pain—Timolol—coronary artery disease	2.64e-05	0.000218	CcSEcCtD
Sorafenib—Dizziness—Losartan—coronary artery disease	2.64e-05	0.000218	CcSEcCtD
Sorafenib—Vomiting—Furosemide—coronary artery disease	2.63e-05	0.000217	CcSEcCtD
Sorafenib—Rash—Furosemide—coronary artery disease	2.6e-05	0.000215	CcSEcCtD
Sorafenib—Dermatitis—Furosemide—coronary artery disease	2.6e-05	0.000215	CcSEcCtD
Sorafenib—Nausea—Captopril—coronary artery disease	2.6e-05	0.000215	CcSEcCtD
Sorafenib—Headache—Furosemide—coronary artery disease	2.59e-05	0.000214	CcSEcCtD
Sorafenib—Gastrointestinal pain—Lisinopril—coronary artery disease	2.53e-05	0.000209	CcSEcCtD
Sorafenib—Vomiting—Losartan—coronary artery disease	2.53e-05	0.000209	CcSEcCtD
Sorafenib—Nausea—Perindopril—coronary artery disease	2.52e-05	0.000208	CcSEcCtD
Sorafenib—Hypersensitivity—Ramipril—coronary artery disease	2.52e-05	0.000208	CcSEcCtD
Sorafenib—Rash—Losartan—coronary artery disease	2.51e-05	0.000207	CcSEcCtD
Sorafenib—Dermatitis—Losartan—coronary artery disease	2.51e-05	0.000207	CcSEcCtD
Sorafenib—Headache—Losartan—coronary artery disease	2.5e-05	0.000206	CcSEcCtD
Sorafenib—Urticaria—Lisinopril—coronary artery disease	2.46e-05	0.000203	CcSEcCtD
Sorafenib—Hypersensitivity—Timolol—coronary artery disease	2.46e-05	0.000203	CcSEcCtD
Sorafenib—Nausea—Furosemide—coronary artery disease	2.45e-05	0.000203	CcSEcCtD
Sorafenib—Asthenia—Ramipril—coronary artery disease	2.45e-05	0.000202	CcSEcCtD
Sorafenib—Body temperature increased—Lisinopril—coronary artery disease	2.45e-05	0.000202	CcSEcCtD
Sorafenib—Abdominal pain—Lisinopril—coronary artery disease	2.45e-05	0.000202	CcSEcCtD
Sorafenib—Pruritus—Ramipril—coronary artery disease	2.42e-05	0.0002	CcSEcCtD
Sorafenib—Asthenia—Timolol—coronary artery disease	2.4e-05	0.000198	CcSEcCtD
Sorafenib—Nausea—Losartan—coronary artery disease	2.37e-05	0.000195	CcSEcCtD
Sorafenib—Pruritus—Timolol—coronary artery disease	2.36e-05	0.000195	CcSEcCtD
Sorafenib—Diarrhoea—Ramipril—coronary artery disease	2.34e-05	0.000193	CcSEcCtD
Sorafenib—Diarrhoea—Timolol—coronary artery disease	2.29e-05	0.000189	CcSEcCtD
Sorafenib—Hypersensitivity—Lisinopril—coronary artery disease	2.28e-05	0.000189	CcSEcCtD
Sorafenib—Dizziness—Ramipril—coronary artery disease	2.26e-05	0.000187	CcSEcCtD
Sorafenib—Asthenia—Lisinopril—coronary artery disease	2.22e-05	0.000184	CcSEcCtD
Sorafenib—Dizziness—Timolol—coronary artery disease	2.21e-05	0.000182	CcSEcCtD
Sorafenib—Pruritus—Lisinopril—coronary artery disease	2.19e-05	0.000181	CcSEcCtD
Sorafenib—Vomiting—Ramipril—coronary artery disease	2.17e-05	0.000179	CcSEcCtD
Sorafenib—Rash—Ramipril—coronary artery disease	2.15e-05	0.000178	CcSEcCtD
Sorafenib—Dermatitis—Ramipril—coronary artery disease	2.15e-05	0.000178	CcSEcCtD
Sorafenib—Headache—Ramipril—coronary artery disease	2.14e-05	0.000177	CcSEcCtD
Sorafenib—Vomiting—Timolol—coronary artery disease	2.12e-05	0.000175	CcSEcCtD
Sorafenib—Diarrhoea—Lisinopril—coronary artery disease	2.12e-05	0.000175	CcSEcCtD
Sorafenib—Rash—Timolol—coronary artery disease	2.11e-05	0.000174	CcSEcCtD
Sorafenib—Dermatitis—Timolol—coronary artery disease	2.1e-05	0.000174	CcSEcCtD
Sorafenib—Headache—Timolol—coronary artery disease	2.09e-05	0.000173	CcSEcCtD
Sorafenib—Dizziness—Lisinopril—coronary artery disease	2.05e-05	0.000169	CcSEcCtD
Sorafenib—Nausea—Ramipril—coronary artery disease	2.03e-05	0.000168	CcSEcCtD
Sorafenib—Nausea—Timolol—coronary artery disease	1.98e-05	0.000164	CcSEcCtD
Sorafenib—Vomiting—Lisinopril—coronary artery disease	1.97e-05	0.000163	CcSEcCtD
Sorafenib—Rash—Lisinopril—coronary artery disease	1.95e-05	0.000161	CcSEcCtD
Sorafenib—Dermatitis—Lisinopril—coronary artery disease	1.95e-05	0.000161	CcSEcCtD
Sorafenib—Headache—Lisinopril—coronary artery disease	1.94e-05	0.00016	CcSEcCtD
Sorafenib—Nausea—Lisinopril—coronary artery disease	1.84e-05	0.000152	CcSEcCtD
Sorafenib—ABCB1—Metabolism—LPL—coronary artery disease	3.95e-07	3.31e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—coronary artery disease	3.95e-07	3.31e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—coronary artery disease	3.95e-07	3.31e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LDLR—coronary artery disease	3.94e-07	3.3e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—coronary artery disease	3.91e-07	3.28e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—coronary artery disease	3.91e-07	3.28e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—coronary artery disease	3.91e-07	3.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—coronary artery disease	3.9e-07	3.27e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOB—coronary artery disease	3.9e-07	3.27e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—coronary artery disease	3.9e-07	3.27e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—coronary artery disease	3.9e-07	3.27e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	3.9e-07	3.26e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTT1—coronary artery disease	3.9e-07	3.26e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—coronary artery disease	3.9e-07	3.26e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—coronary artery disease	3.9e-07	3.26e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—coronary artery disease	3.89e-07	3.26e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—coronary artery disease	3.88e-07	3.25e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOB—coronary artery disease	3.87e-07	3.24e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—coronary artery disease	3.86e-07	3.23e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—coronary artery disease	3.86e-07	3.23e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF2—coronary artery disease	3.85e-07	3.23e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCLC—coronary artery disease	3.85e-07	3.23e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CETP—coronary artery disease	3.85e-07	3.23e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CD36—coronary artery disease	3.85e-07	3.22e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—coronary artery disease	3.83e-07	3.21e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—coronary artery disease	3.83e-07	3.21e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—coronary artery disease	3.83e-07	3.21e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—coronary artery disease	3.83e-07	3.2e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—coronary artery disease	3.82e-07	3.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SDC1—coronary artery disease	3.81e-07	3.19e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—coronary artery disease	3.81e-07	3.19e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—coronary artery disease	3.8e-07	3.19e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—coronary artery disease	3.8e-07	3.18e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPP2CA—coronary artery disease	3.8e-07	3.18e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—coronary artery disease	3.8e-07	3.18e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—coronary artery disease	3.8e-07	3.18e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—coronary artery disease	3.78e-07	3.17e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—coronary artery disease	3.77e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—coronary artery disease	3.76e-07	3.15e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOA1—coronary artery disease	3.76e-07	3.15e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CD36—coronary artery disease	3.76e-07	3.15e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK1—coronary artery disease	3.76e-07	3.15e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK1—coronary artery disease	3.76e-07	3.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—coronary artery disease	3.74e-07	3.13e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—coronary artery disease	3.73e-07	3.12e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—coronary artery disease	3.72e-07	3.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—coronary artery disease	3.71e-07	3.11e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPP2CA—coronary artery disease	3.71e-07	3.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—coronary artery disease	3.69e-07	3.09e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JAK2—coronary artery disease	3.69e-07	3.09e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—coronary artery disease	3.67e-07	3.07e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—coronary artery disease	3.65e-07	3.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—coronary artery disease	3.64e-07	3.05e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—coronary artery disease	3.63e-07	3.05e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—coronary artery disease	3.63e-07	3.04e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—coronary artery disease	3.63e-07	3.04e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—coronary artery disease	3.62e-07	3.03e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—coronary artery disease	3.61e-07	3.03e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—coronary artery disease	3.61e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—coronary artery disease	3.6e-07	3.02e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	3.6e-07	3.02e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—coronary artery disease	3.6e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMA6—coronary artery disease	3.6e-07	3.01e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMB5—coronary artery disease	3.6e-07	3.01e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—coronary artery disease	3.58e-07	3e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK1—coronary artery disease	3.56e-07	2.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—coronary artery disease	3.56e-07	2.98e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—coronary artery disease	3.56e-07	2.98e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK1—coronary artery disease	3.56e-07	2.98e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CD36—coronary artery disease	3.54e-07	2.97e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—coronary artery disease	3.54e-07	2.96e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—coronary artery disease	3.53e-07	2.96e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—coronary artery disease	3.52e-07	2.95e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—coronary artery disease	3.52e-07	2.95e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—coronary artery disease	3.51e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—coronary artery disease	3.51e-07	2.94e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—coronary artery disease	3.51e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CD36—coronary artery disease	3.51e-07	2.94e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—coronary artery disease	3.5e-07	2.93e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPP2CA—coronary artery disease	3.5e-07	2.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMGCR—coronary artery disease	3.48e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—coronary artery disease	3.48e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARGC1A—coronary artery disease	3.47e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPP2CA—coronary artery disease	3.47e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—coronary artery disease	3.47e-07	2.9e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—coronary artery disease	3.45e-07	2.89e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—coronary artery disease	3.44e-07	2.88e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—coronary artery disease	3.43e-07	2.88e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—coronary artery disease	3.43e-07	2.87e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—coronary artery disease	3.4e-07	2.85e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—coronary artery disease	3.4e-07	2.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—coronary artery disease	3.39e-07	2.84e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—coronary artery disease	3.39e-07	2.84e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—coronary artery disease	3.38e-07	2.83e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—coronary artery disease	3.37e-07	2.82e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—coronary artery disease	3.37e-07	2.82e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—coronary artery disease	3.36e-07	2.81e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—coronary artery disease	3.35e-07	2.81e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—coronary artery disease	3.33e-07	2.79e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—coronary artery disease	3.31e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—coronary artery disease	3.31e-07	2.78e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOB—coronary artery disease	3.31e-07	2.77e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—coronary artery disease	3.29e-07	2.76e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—coronary artery disease	3.28e-07	2.74e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—coronary artery disease	3.27e-07	2.74e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—coronary artery disease	3.27e-07	2.74e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—coronary artery disease	3.26e-07	2.73e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—coronary artery disease	3.26e-07	2.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—coronary artery disease	3.26e-07	2.73e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—coronary artery disease	3.24e-07	2.72e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—coronary artery disease	3.23e-07	2.7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—coronary artery disease	3.22e-07	2.69e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	3.21e-07	2.69e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—coronary artery disease	3.21e-07	2.69e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK1—coronary artery disease	3.2e-07	2.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLCB1—coronary artery disease	3.2e-07	2.68e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—coronary artery disease	3.2e-07	2.68e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—coronary artery disease	3.19e-07	2.67e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—coronary artery disease	3.17e-07	2.66e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—coronary artery disease	3.17e-07	2.66e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—coronary artery disease	3.16e-07	2.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—coronary artery disease	3.16e-07	2.64e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—coronary artery disease	3.14e-07	2.63e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—coronary artery disease	3.13e-07	2.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—coronary artery disease	3.13e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—coronary artery disease	3.12e-07	2.62e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—coronary artery disease	3.11e-07	2.61e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ABCA1—coronary artery disease	3.1e-07	2.6e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—coronary artery disease	3.1e-07	2.59e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—coronary artery disease	3.09e-07	2.59e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—coronary artery disease	3.09e-07	2.59e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—coronary artery disease	3.08e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—coronary artery disease	3.08e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—coronary artery disease	3.08e-07	2.58e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—coronary artery disease	3.06e-07	2.56e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK1—coronary artery disease	3.05e-07	2.56e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—coronary artery disease	3.05e-07	2.55e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—coronary artery disease	3.05e-07	2.55e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—coronary artery disease	3.05e-07	2.55e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—coronary artery disease	3.01e-07	2.52e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—coronary artery disease	3.01e-07	2.52e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—coronary artery disease	3.01e-07	2.52e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CD36—coronary artery disease	3e-07	2.51e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—coronary artery disease	2.98e-07	2.5e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPP2CA—coronary artery disease	2.96e-07	2.48e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—coronary artery disease	2.96e-07	2.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—coronary artery disease	2.96e-07	2.48e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—coronary artery disease	2.95e-07	2.47e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.93e-07	2.46e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—coronary artery disease	2.92e-07	2.45e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—coronary artery disease	2.92e-07	2.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—coronary artery disease	2.91e-07	2.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—coronary artery disease	2.89e-07	2.42e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—coronary artery disease	2.89e-07	2.42e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—coronary artery disease	2.89e-07	2.42e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—coronary artery disease	2.89e-07	2.42e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK1—coronary artery disease	2.85e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—coronary artery disease	2.85e-07	2.39e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—coronary artery disease	2.85e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—coronary artery disease	2.84e-07	2.38e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—coronary artery disease	2.78e-07	2.33e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—coronary artery disease	2.74e-07	2.29e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—coronary artery disease	2.74e-07	2.29e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—coronary artery disease	2.73e-07	2.29e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—coronary artery disease	2.72e-07	2.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—coronary artery disease	2.7e-07	2.26e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—coronary artery disease	2.7e-07	2.26e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—coronary artery disease	2.7e-07	2.26e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—coronary artery disease	2.68e-07	2.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	2.68e-07	2.24e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—coronary artery disease	2.66e-07	2.23e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—coronary artery disease	2.66e-07	2.23e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—coronary artery disease	2.66e-07	2.23e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—coronary artery disease	2.66e-07	2.23e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—coronary artery disease	2.66e-07	2.23e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—coronary artery disease	2.65e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—coronary artery disease	2.65e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—coronary artery disease	2.63e-07	2.2e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—coronary artery disease	2.62e-07	2.19e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—coronary artery disease	2.61e-07	2.18e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—coronary artery disease	2.6e-07	2.17e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—coronary artery disease	2.58e-07	2.16e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—coronary artery disease	2.56e-07	2.15e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOB—coronary artery disease	2.55e-07	2.14e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—coronary artery disease	2.54e-07	2.13e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—coronary artery disease	2.53e-07	2.12e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—coronary artery disease	2.52e-07	2.11e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—coronary artery disease	2.51e-07	2.11e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	2.5e-07	2.1e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—coronary artery disease	2.49e-07	2.08e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—coronary artery disease	2.49e-07	2.08e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—coronary artery disease	2.48e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—coronary artery disease	2.48e-07	2.08e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—coronary artery disease	2.48e-07	2.08e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK1—coronary artery disease	2.46e-07	2.06e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—coronary artery disease	2.46e-07	2.06e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—coronary artery disease	2.45e-07	2.05e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—coronary artery disease	2.44e-07	2.04e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—coronary artery disease	2.42e-07	2.03e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—coronary artery disease	2.38e-07	1.99e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—coronary artery disease	2.35e-07	1.97e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—coronary artery disease	2.34e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—coronary artery disease	2.33e-07	1.95e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—coronary artery disease	2.32e-07	1.94e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD36—coronary artery disease	2.31e-07	1.94e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—coronary artery disease	2.3e-07	1.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	2.29e-07	1.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—coronary artery disease	2.27e-07	1.9e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—coronary artery disease	2.27e-07	1.9e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—coronary artery disease	2.27e-07	1.9e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—coronary artery disease	2.19e-07	1.84e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—coronary artery disease	2.19e-07	1.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—coronary artery disease	2.17e-07	1.81e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—coronary artery disease	2.14e-07	1.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—coronary artery disease	2.14e-07	1.79e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—coronary artery disease	2.12e-07	1.78e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—coronary artery disease	2.11e-07	1.77e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—coronary artery disease	2.09e-07	1.75e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—coronary artery disease	2.08e-07	1.75e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—coronary artery disease	2.07e-07	1.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—coronary artery disease	2.04e-07	1.71e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—coronary artery disease	2.02e-07	1.7e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—coronary artery disease	2.02e-07	1.69e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—coronary artery disease	1.98e-07	1.66e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—coronary artery disease	1.89e-07	1.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—coronary artery disease	1.89e-07	1.59e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—coronary artery disease	1.85e-07	1.55e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—coronary artery disease	1.81e-07	1.52e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—coronary artery disease	1.78e-07	1.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—coronary artery disease	1.75e-07	1.47e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—coronary artery disease	1.75e-07	1.46e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—coronary artery disease	1.6e-07	1.34e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—coronary artery disease	1.6e-07	1.34e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—coronary artery disease	1.55e-07	1.3e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—coronary artery disease	1.53e-07	1.28e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—coronary artery disease	1.51e-07	1.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—coronary artery disease	1.43e-07	1.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—coronary artery disease	1.4e-07	1.17e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—coronary artery disease	1.4e-07	1.17e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—coronary artery disease	1.32e-07	1.1e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—coronary artery disease	1.31e-07	1.1e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—coronary artery disease	1.31e-07	1.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—coronary artery disease	1.17e-07	9.8e-07	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—coronary artery disease	1.14e-07	9.56e-07	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—coronary artery disease	1.12e-07	9.34e-07	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—coronary artery disease	1.08e-07	9.01e-07	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—coronary artery disease	1.07e-07	8.93e-07	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—coronary artery disease	9.11e-08	7.63e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	8.61e-08	7.21e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—coronary artery disease	7.03e-08	5.89e-07	CbGpPWpGaD
